Paratek Pharmaceuticals Inc. waited less than 24 hours for word late Tuesday of its second and bigger win with FDA approval of lead candidate, omadacycline, branded Nuzyra. Earlier in the day, the Boston-based company received word that Seysara (sarecycline) was greenlighted by the FDA to treat inflammatory moderate to severe acne in patients 9 and older. (See BioWorld, Oct. 3, 2018.)